Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Thoracic 1Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 77Leukemia 74Leukemia, Lymphocytic, Chronic, B-Cell 68Myelodysplastic Syndromes 56Lymphoma 49Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Lymphoma, Non-Hodgkin 45Multiple Myeloma 43Leukemia, Myelogenous, Chronic, BCR-ABL Positive 38Hodgkin Disease 36Melanoma 25Hematologic Neoplasms 25Recurrence 19Neoplasms 17Myeloproliferative Disorders 17Neoplasm Metastasis 15Lymphoma, Follicular 15Primary Myelofibrosis 14Neoplasms, Plasma Cell 14Lymphoma, Large B-Cell, Diffuse 14Lymphoma, Mantle-Cell 13Skin Neoplasms 11Graft vs Host Disease 11Burkitt Lymphoma 11Anemia, Refractory, with Excess of Blasts 11Lymphoma, B-Cell, Marginal Zone 10Lymphoma, B-Cell 10Leukemia, Myelomonocytic, Chronic 9Hematologic Diseases 8Breast Neoplasms 8

Interventions

pembrolizumab 37Paclitaxel 36Carboplatin 31Cyclophosphamide 22Albumin-Bound Paclitaxel 20atezolizumab 16130-nm albumin-bound paclitaxel 16Taxes 15Doxorubicin 15Cisplatin 13Capecitabine 13Nivolumab 10Docetaxel 8olaparib 7Gemcitabine 6Everolimus 6talazoparib 5durvalumab 5Magnetic Resonance Spectroscopy 5Biopsy 5Bevacizumab 5veliparib 4spartalizumab 4sacituzumab govitecan 4pegfilgrastim 4liposomal doxorubicin 4eribulin 4Specimen Handling 4Immunoglobulin G 4trilaciclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Triple Negative Breast Neoplasms × fludarabine × Clear all
NCT05035407 2025-12-02

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
36 enrolled 7 charts
Breast

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04639245 2023-08-03

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
1 enrolled 6 charts
BreastGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡